BioSpace News Archive

BeiGene, Ltd., a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, reported recent business highlights, anticipated upcoming milestones, and financial results for the second quarter and first half of 2020.

Y-mAbs Therapeutics, Inc. a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, reported financial results for the second quarter 2020.

Cara Therapeutics, Inc. announced that Derek Chalmers, Ph.D., D.Sc., President and Chief Executive Officer, will participate in a fireside chat at the Canaccord Genuity 40th Annual Growth Conference on Thursday, August 13, 2020 at 8:00 a.m. ET.

ASCEND results expected to support STS101 NDA filing in Q4 2021

Principia Biopharma Inc., a late-stage biopharmaceutical company focused on developing treatments for immune mediated diseases, announced financial results for the second quarter ended June 30, 2020.

Editas Medicine, Inc. announced it has regained full global rights to research, develop, manufacture, and commercialize its ocular medicines, including EDIT-101 for the treatment of Leber congenital amaurosis 10, which were previously shared within a strategic research and development alliance with Allergan, which has since been acquired by AbbVie.

Iovance Biotherapeutics, Inc., a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, reported second quarter 2020 financial results and provided a corporate update.

Entasis Therapeutics Holdings Inc., a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, announced its second quarter 2020 financial results and provided a business update.

Capricor Therapeutics announced its financial results for the second quarter ending June 30, 2020 and provided a corporate update.

Nabriva Therapeutics plc announced its financial results for the three months ended June 30, 2020 and provided a corporate update.